Bio Path Valuation
| BPTH Stock | USD 0.06 0 2.17% |
Bio Path seems to be fairly valued based on Macroaxis valuation methodology. Our model approximates the value of Bio Path Holdings from analyzing the firm fundamentals such as Shares Owned By Institutions of 7.41 %, current valuation of 531.06 K, and Return On Equity of -11.6 as well as examining its technical indicators and probability of bankruptcy. . In general, most investors favor purchasing undervalued instruments and trading away overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
Fairly Valued
Today
Please note that Bio Path's price fluctuation is out of control at this time. Calculation of the real value of Bio Path Holdings is based on 3 months time horizon. Increasing Bio Path's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Bio otc stock is determined by what a typical buyer is willing to pay for full or partial control of Bio Path Holdings. Since Bio Path is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Bio OTC Stock. However, Bio Path's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.0587 | Real 0.0583 | Hype 0.06 | Naive 0.0455 |
The intrinsic value of Bio Path's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Bio Path's stock price.
Estimating the potential upside or downside of Bio Path Holdings helps investors to forecast how Bio otc stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Bio Path more accurately as focusing exclusively on Bio Path's fundamentals will not take into account other important factors: Bio Path Total Value Analysis
Bio Path Holdings is currently anticipated to have valuation of 531.06 K with market capitalization of 1.21 M, debt of 113 K, and cash on hands of 17.02 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Bio Path fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
531.06 K | 1.21 M | 113 K | 17.02 M |
Bio Path Asset Utilization
One of the ways to look at asset utilization of Bio is to check how much profit was generated for every dollar of assets it reports. Bio Path Holdings shows a negative utilization of assets of -1.94 percent, losing $0.0194 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Bio Path Holdings shows how discouraging it operates for each dollar spent on its assets.Bio Path Ownership Allocation
Almost 92.59 percent of Bio Path outstanding shares are held by general public with 7.41 % by other corporate entities.Bio Path Profitability Analysis
Net Loss for the year was (16.08 M) with profit before overhead, payroll, taxes, and interest of 0.About Bio Path Valuation
An absolute valuation paradigm, as applied to Bio OTC Stock, attempts to find the value of Bio Path Holdings based on its fundamental and basic technical indicators. By analyzing Bio Path's financials, quarterly and monthly indicators, and their related drivers, such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Bio Path's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Bio Path. We calculate exposure to Bio Path's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Bio Path's related companies.Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas. Bio-Path Holdings operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10 people.
8 Steps to conduct Bio Path's Valuation Analysis
OTC Stock's valuation is the process of determining the worth of any otc stock in monetary terms. It estimates Bio Path's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of otc stock valuation is a single number representing a OTC Stock's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Bio Path's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Bio Path's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Bio Path's revenue streams: Identify Bio Path's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Bio Path's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Bio Path's growth potential: Evaluate Bio Path's management, business model, and growth potential.
- Determine Bio Path's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the OTC Stock's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Bio Path's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for Bio OTC Stock analysis
When running Bio Path's price analysis, check to measure Bio Path's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Path is operating at the current time. Most of Bio Path's value examination focuses on studying past and present price action to predict the probability of Bio Path's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Path's price. Additionally, you may evaluate how the addition of Bio Path to your portfolios can decrease your overall portfolio volatility.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |